



ACCURATELY DETECT ANTIBIOTIC RESISTANCE WITH A **NEW** RANGE OF MICROSCAN PANELS

To learn more about Beckman Coulter's microbiology solutions, visit:
www.beckmancoulter.com/microbiology





As the prevalence of antimicrobial resistance continues to increase, the value of accurate MIC testing and ultimately the best patient outcome has become more critical than ever.

For over 40 years, the MicroScan AST system has been providing accurate and trusted bacterial identification and susceptibility results utilizing its broth microdilution technology. **MicroScan's technology has been a key factor in detecting and fighting against antibiotic resistance.**

We continue our fight against antimicrobial resistance by launching new panels: eight Gram-negative panels and two panels targeting multi-drug resistance.

The two MDR (ID/AST combo and a MIC) panels feature the innovative antibiotics *Meropenem-vaborbactam* and *Eravacycline*. These MDR panels also offer the addition of combination drugs ceftazidime-avibactam and ceftolozane-tazobactam and established antibiotics like Colistin and Meropenem and therefore is a true comprehensive MDR product.

- **Meropenem-vaborbactam:** recommended for treating multi-drug resistant *Enterobacterales* (*Enterobacteriaceae*) containing ESβLs, amp-C, and KPC carbapenemases in complicated urinary tract infections including pyelonephritis – **NEW!**
- **Eravacycline:** a newly developed antibiotic recommended in certain regions to treat complicated urinary tract infections and intra-abdominal infections – **NEW!**
- **Ceftolozane-tazobactam:** is recommended for the treatment of multi-drug resistant *Enterobacterales* (*Enterobacteriaceae*) containing ESβLs and other beta-lactamases of the following groups: TEM, SHV, CTX-M, and OXA, and *P. aeruginosa* in select complicated infections – **NEW!**
- **Ceftazidime-avibactam:** is recommended for the treatment of ceftazidime non-susceptible beta-lactamase producing (e.g., ESβL, KPC and AmpC) *Enterobacterales* (*Enterobacteriaceae*) and *Pseudomonas (P.) aeruginosa* in select complicated infections and hospital-acquired bacterial pneumonia – **NEW!**

	PANEL NAME	NEG MDR MIC 2	NEG MDR COMBO 100
	MICROSCAN CATALOG NUMBER	C80302	C80306
ANTIMICROBIAL AGENT	Abbv	µg/mL	µg/mL
Amikacin	Ak	8 - 16	8-16
Amoxicillin-K Clavulanate-E	Aug-E	4/2 - 8/2, 32/2	4/2-8/2,32/2
Ampicillin	Am	4 - 8	4-8
Ampicillin-sulbactam	A/S	-	-
Aztreonam	Azt	1 - 4, 16	1-4,16
Cefepime	Cpe	0.5 - 8	1-8
Cefixime	Cfe	-	-
Cefotaxime	Cft	0.5 - 32	1-16
Cefotaxime-K Clavulanate	Cft/CA	0.25/4 - 4/4	0.25/4-0.5/4,4/4
Cefoxitin	Cfx	8 - 16	8
Ceftazidime	Caz	0.5 - 32	1-16
Ceftazidime-avibactam	CZA	2/4 - 8/4	8/4
Ceftazidime-K Clavulanate	Caz/CA	0.25/4 - 4/4	0.25/4-0.5/4,2/4
Ceftolozane-tazobactam	C/T	0.5/4 - 4/4	2/4-4/4
Cefuroxime	Crm	4 - 8	-
Cephalexin	CFL	-	-
Chloramphenicol	C	-	-
Ciprofloxacin	Cp	0.06, 0.25 - 1	0.25-1
Colistin	Cl	2 - 4	2-4
Eravacycline	Erv	0.5	-
Ertapenem	Etp	0.12 - 1	0.12-0.5
Fosfomycin	Fos	8, 32 - 64	32-64
Gentamicin	Gm	2 - 4	2-4
Imipenem	Imp	1 - 4	-
Levofloxacin	Lvx	0.5 - 1	0.5-1
Mecillinam	Mec	-	-
Meropenem	Mer	0.12, 1 - 32	0.12,2-8
Meropenem-vaborbactam	MEV	4/8 - 16/8	8/8
Minocycline	Min	-	-
Nalidixic Acid	NA	-	16
Nitrofurantoin	Fd	-	-
Norfloxacin	Nxn	-	-
Piperacillin	Pi	-	-
Piperacillin/Tazobactam	P/T	4/4-16/4	8/4-16/4
Tetracycline	Te	-	-
Ticarcillin	Ti	8-16	-
Tigecycline	Tgc	0.5-1	-
Tobramycin	To	2-4	2-4
Trimethoprim	T	-	-
Trimethoprim/Sulfamethoxazole	T/S	2/38-4/76	2/38-4/76



Continuing the expansion of routine Gram-negative testing

In routine laboratories, 60% of ASTs target Gram-negative testing. To continue supporting laboratories in testing their highest volume organism group, the majority of our Gram-negative panels are designed towards this testing.

These new panels feature the addition of the new EUCAST uncomplicated UTI breakpoint 8mg/L for Fosfomycin and Cephalexin.

These panels and MicroScan's PROMPT® system are designed to allow lean workflow and reduce ancillary testing with both first and second line antibiotics available.

MicroScan's latest routine Gram-negative new panels offer:

- **Cephalexin:** as a primary treatment for Enterobacterales (Enterobacteriaceae) uncomplicated urinary infection – **NEW!**
- **Fosfomycin 8mg/L:** was recently introduced in the EUCAST ver 12 guidelines for the oral treatment of uncomplicated tract infection caused by E.coli – **IMPROVED!**
- **Enhanced formulation of Imipenem:** allows for the full reporting of Acinetobacter spp – **IMPROVED!**

PANEL CONFIGURATIONS – NEG MIC	PANEL NAME	NEG MIC 62	NEG MIC 63	NEG MIC NF 64	NEG MDR MIC 2
	MICROSCAN CATALOG NUMBER	C80299	C80300	C80301	C80302
ANTIMICROBIAL AGENT	Abbv	µg/mL	µg/mL	µg/mL	µg/mL
Amikacin	Ak	8 - 16	8 - 16	4 - 16	8 - 16
Amoxicillin-K Clavulanate-E	Aug-E	4/2 - 8/2, 32/2	4/2 - 8/2, 32/2	8/2	4/2 - 8/2, 32/2
Ampicillin	Am	4 - 8	4 - 8	-	4 - 8
Ampicillin-sulbactam	A/S	8/4 - 16/8	-	-	-
Aztreonam	Azt	1 - 16	1 - 16	2 - 16	1 - 4, 16
Cefepime	Cpe	1 - 8	1 - 8	1 - 32	0.5 - 8
Cefixime	Cfe	1	1	-	-
Cefotaxime	Cft	1 - 32	1 - 32	-	0.5 - 32
Cefotaxime-K Clavulanate	Cft/CA	0.25/4 - 4/4	0.25/4 - 4/4	-	0.25/4 - 4/4
Cefoxitin	Cfx	8	8	-	8 - 16
Ceftazidime	Caz	1 - 32	1 - 32	4 - 64	0.5 - 32
Ceftazidime-avibactam	CZA	2/4 - 8/4	2/4 - 8/4	2/4 - 32/4	2/4 - 8/4
Ceftazidime-K Clavulanate	Caz/CA	0.25/4 - 4/4	0.25/4 - 4/4	-	0.25/4 - 4/4
Ceftolozane-tazobactam	C/T	1/4 - 4/4	1/4 - 4/4	0.5/4 - 8/4	0.5/4 - 4/4
Cefuroxime	Crm	8	8	-	4 - 8
Cephalexin	CFL	16	-	-	-
Chloramphenicol	C	8	8	8 - 16	-
Ciprofloxacin	Cp	0.06, 0.25 - 1	0.06 - 1	0.25 - 2	0.06, 0.25 - 1
Colistin	Cl	2 - 4	2 - 4	2 - 4	2 - 4
Eravacycline	Erv	-	-	0.5	0.5
Ertapenem	Etp	0.12, 0.5 - 1	0.06 - 1	-	0.12 - 1
Fosfomycin	Fos	8, 32	8 - 64	16 - 64	8, 32 - 64
Gentamicin	Gm	2 - 4	2 - 4	4 - 8	2 - 4
Imipenem	Imp	1 - 4	1 - 4	1 - 16	1 - 4
Levofloxacin	Lvx	0.5 - 1	0.5 - 1	0.5 - 4	0.5 - 1
Mecillinam	Mec	8	-	-	-
Meropenem	Mer	0.12, 1 - 8	0.12, 1 - 32	1 - 32	0.12, 1 - 32
Meropenem-vaborbactam	MEV	-	8/8	4/8 - 32/8	4/8 - 16/8
Minocycline	Min	-	-	2-8	-
Nalidixic Acid	NA	16	16	-	-
Nitrofurantoin	Fd	64	64	-	-
Norfloxacin	Nxn	0.5-1	0.5-1	-	-
Piperacilin	Pi	8-16	-	8-64	-
Piperacillin/Tazobactam	P/T	4/4-16/4	4/4-16/4	4/4-64/4	4/4-16/4
Tetracycline	Te	-	8	4-8	-
Ticarcillin	Ti	8-16	-	16-64	8-16
Ticarcillin/Clavulanic Acid	Tim	-	-	8/2 - 64/2	-
Tigecycline	Tgc	0.5	0.5-1	0.5-1	0.5-1
Tobramycin	To	2-4	2-4	1-16	2-4
Trimethoprim	T	2-4	-	-	-
Trimethoprim/ Sulfamethoxazole	T/S	2/38-4/76	2/38-4/76	1/19-4/76	2/38-4/76

PANEL CONFIGURATIONS - NEG COMBO PANELS	PANEL NAME	NEG URINE COMBO 98	NEG COMBO 99	NEG BP COMBO 53
	MICROSCAN CATALOG NUMBER	C80303	C80304	C80305
ANTIMICROBIAL AGENT	Abbv	µg/mL	µg/mL	µg/mL
Amikacin	Ak	8-16	8-16	8-16
Amoxicillin-K Clavulanate-E	Aug-E	8/2,32/2	4/2-8/2	4/2-8/2,32/2
Ampicillin	Am	4-8	4-8	4-8
Ampicillin-sulbactam	A/S	-	-	8/4
Aztreonam	Azt	1-4,16	1-4,16	1,4,16
Cefepime	Cpe	1,4-8	1-8	1-8
Cefixime	Cfe	-	-	-
Cefotaxime	Cft	1-16	1-16	1-16
Cefotaxime-K Clavulanate	Cft/CA	0.25/4-0.5/4,4/4	0.25/4-0.5/4,4/4	0.5/4,4/4
Cefoxitin	Cfx	8	8	8
Ceftazidime	Caz	1-16	1-16	1-16
Ceftazidime-avibactam	CZA	-	-	-
Ceftazidime-K Clavulanate	Caz/CA	0.25/4-0.5/4,2/4	0.25/4-0.5/4,2/4	0.25/4,2/4
Ceftolozane-tazobactam	C/T	-	-	-
Cefuroxime	Crm	8	8	8
Cephalexin	CFL	-	-	16
Chloramphenicol	C	-	-	8
Ciprofloxacin	Cp	0.06,0.25-1	0.06,0.25-1	0.06,0.25-1
Colistin	Cl	2-4	2-4	2-4
Eravacycline	Erv	-	-	-
Ertapenem	Etp	0.12-0.5	0.12-0.5	0.12,0.5
Fosfomycin	Fos	8,32	32	8
Gentamicin	Gm	2-4	2-4	2-4
Imipenem	Imp	2-4	2-4	2-4
Levofloxacin	Lvx	0.5-1	0.5-1	0.5-1
Mecillinam	Mec	-	-	8
Meropenem	Mer	0.12,2-8	0.12,2-8	0.12,2,8
Meropenem-vaborbactam	MEV	-	-	-
Minocycline	Min	-	-	-
Nalidixic Acid	NA	16	16	-
Nitrofurantoin	Fd	64	-	64
Norfloxacin	Nxn	0.5-1	-	-
Piperacillin	Pi	-	-	8-16
Piperacillin/Tazobactam	P/T	8/4-16/4	4/4-16/4	8/4-16/4
Tetracycline	Te	-	-	-
Ticarcillin	Ti	-	-	-
Tigecycline	Tgc	-	0.5	-
Tobramycin	To	2-4	2-4	2-4
Trimethoprim	T	-	-	4
Trimethoprim/Sulfamethoxazole	T/S	2/38-4/76	2/38-4/76	2/38-4/76



Streamline your workflow with a single Gram-positive panel for a biochemical ID and wide range AST

Methicillin-resistant *Staphylococcus aureus* (MRSA) and Vancomycin-resistant Enterococci (VRE) infections are still prevalent in all health care settings. These two-gram positive multi-drug resistant organisms are monitored in hospital settings and community settings.

MicroScan's latest Gram-positive panels design focuses on streamlining a laboratory workflow whilst maintaining a wide variety of antibiotics addressing both routine Gram-positive infections and tackling the known hospital-acquired infections MRSA and VRE.

MicroScan's latest Gram-positive new panels offer:

- Tigecycline: a glycycline antibiotic not affected by major, in class resistance mechanisms, with activity against MRSA and VRE infections
- Ceftaroline: lower dilutions of Ceftaroline, a broad-spectrum cephalosporin with anti-MRSA activity for use in acute bacterial skin and skin structure infections
- Clindamycin: lower dilutions of Clindamycin to assist in the treatment of MSSA and MRSA
- Enhanced formulation of Vancomycin allowing 16-20 hour reads of Enterococci and improving the performance of *Staphylococcus aureus* when using the Prompt Inoculation System
- Enhanced formulation of Daptomycin to improve accuracy for Staphylococci and Enterococci
- A single MIC panel utilizing workflow with integrated MALDI-TOF identification
- A single panel combining traditional biochemical identifications with MICs
- The new features of this panel software also allow predictive susceptibility, as stated in EUCAST Ver 12

PANEL CONFIGURATIONS - GRAM-POSITIVE PANELS	PANEL NAME	POS MIC 40	POS COMBO 48	POS COMBO 49
	MICROSCAN CATALOG NUMBER	C80307	C80308	C80309
ANTIMICROBIAL AGENT	Abbv	µg/mL	µg/mL	µg/mL
Amikacin	Ak	8-16	-	-
Amoxicillin/K Clavulanate	Aug	4/2-8/4	-	-
Ampicillin	Am	2-8	2-8	2-8
Cefoxitin Screen	CfxS	4	4	4
Ceftaroline	Cpt	0.5-2	1-2	1-2
Chloramphenicol	C	8	-	-
Ciprofloxacin	Cp	1-4	1-4	1-4
Clarithromycin	Cla	0.25-2	-	-
Clindamycin	Cd	0.12-1	0.25-1	0.25-1
Daptomycin	Dap	0.25-4	0.5-1	0.5-1
Erythromycin	E	0.25-4	0.25-4	0.25-4
Fosfomycin	Fos	32-64	32	32
Fusidic Acid	FA	2	2	2
Gentamicin	Gm	1-2	1-2	1-2
Gentamicin Synergy Screen	GmS	500	500	500
Imipenem	Imp	2-4	2-4	2-4
Inducible Clindamycin	ICd	4/0.5	4/0.5	4/0.5
Kanamycin	K	8	-	-
Levofloxacin	Lvx	1-4	1-4	1-4
Linezolid	Lzd	1-4	2-4	2-4
Moxifloxacin	Mxf	0.25-0.5	0.25-0.5	0.25-0.5
Mupirocin	Mup	4,256	-	4,256
Nitrofurantoin	Fd	64	64	64
Oxacillin	Ox	0.25-2	0.25-2	0.25-2
Penicillin	P	0.06-0.25	0.12-0.25	0.12-0.25
Pristinamycin	Prs	1-2	1-2	-
Rifampin	Rif	0.5-2	0.5-2	0.5-2
Streptomycin Synergy Screen	StS	1000	1000	1000
Synercid	Syn	1-4	-	-
Teicoplanin	Tei	1-16	1-4	1-4
Tetracycline	Te	1-2	1-2	1-2
Tigecycline	Tgc	0.12-0.5	0.12-0.5	0.12-0.5
Tobramycin	To	1-2	1-2	1-2
Trimethoprim/Sulfamethoxazole	T/S	1/19-4/76	1/19-4/76	1/19-4/79
Vancomycin	Va	0.25-16	0.25-8	0.25-8

This brochure is intended for the distribution outside U.S.

© 2022 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

For Beckman Coulter's worldwide office locations and phone numbers, please visit www.beckmancoulter.com/contact

BR-4030702 | 2022-10220

